TAK Takeda Pharmaceutical
- Official Name: Takeda Pharmaceutical Company Limited
- Headquarters: 75 Sidney Street Cambridge, MASSACHUSETTS 02139, US
- CEO: Christophe Weber
- Website: takeda.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1R | Won by 0.412 | (2.652) - (3.064) | ||
| 2025-07-18 | 1 | Won by 5.310 | 2.678 - (2.632) | ||
| 2025-07-25 | 2 | Won by 4.627 | 3.459 - (1.168) | ||
| 2025-07-29 | 2R | Lost by 0.071 | 0.585 - 0.656 | ||
| 2025-08-01 | 3 | Won by 15.735 | 9.652 - (6.083) | ||
| 2025-08-08 | 4 | Won by 9.104 | 5.092 - (4.012) | ||
| 2025-08-15 | 5 | Won by 3.917 | 3.917 - 0.000 | ||
| 2025-08-22 | 6 | Won by 1.498 | 3.094 - 1.596 | ||
| 2025-08-29 | 7 | Lost by 2.731 | (3.609) - (0.878) | ||
| 2025-09-05 | 8 | Won by 4.622 | 3.384 - (1.238) | ||
| 2025-09-12 | 9 | Won by 2.644 | (2.312) - (4.956) | ||
| 2025-09-19 | 10 | Lost by 2.276 | (0.274) - 2.002 | ||
| 2025-09-26 | 11 | Lost by 0.354 | (2.378) - (2.024) | ||
| 2025-10-03 | 12 | Lost by 3.937 | (0.874) - 3.063 | ||
| 2025-10-10 | 13 | Lost by 0.976 | (6.000) - (5.024) | ||
| 2025-10-17 | 14 | Lost by 1.468 | 2.612 - 4.080 | ||
| 2025-10-24 | 15 | Lost by 4.452 | (0.228) - 4.224 |
Latest News
SeekingAlpha - 2026-09-01
Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data
SeekingAlpha - 2026-08-31
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
Benzinga - 2026-08-31
Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug
The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offering an effective new hematocrit control.
Show more
Benzinga - 2026-08-23
Takeda’s ORZEYFUL Wins Japan Approval For Narcolepsy Type 1 After Phase 3 Studies Show Significant Improvements Across Evaluated Symptoms
SeekingAlpha - 2026-08-19
Silence Therapeutics: Making Some Recent Noise
Benzinga - 2026-08-13
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Benzinga - 2026-08-13
Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’
Benzinga - 2026-08-10
Department Of Veterans Affairs Awards Takeda $5.6B Contract for Drugs And Biologicals Through 2031
SeekingAlpha - 2026-08-07
Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern
Yahoo - 2026-08-06
Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead
Yahoo - 2026-08-06
Takeda approval ushers in new wave of sleep drugs
Benzinga - 2026-08-06
Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval
Yahoo - 2026-08-06
Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ...
Yahoo - 2026-08-05
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Benzinga - 2026-08-05
Takeda's ORZEYFUL Wins FDA Approval As First Orexin Therapy For Narcolepsy Type 1; U.S. Launch Planned Following DEA Scheduling
Yahoo - 2026-08-05
AC Immune First Half 2026 Financial and Corporate Update
SeekingAlpha - 2026-08-03
Takeda Pharmaceutical Company Limited (TAK) Q1 2026 Earnings Call Transcript
Yahoo - 2026-07-31
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate
Benzinga - 2026-07-30
Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial
SeekingAlpha - 2026-07-30
Takeda Pharmaceutical Company Limited (TAK) Q1 2027 Earnings Call Transcript
Yahoo - 2026-07-30
Takeda Pharmaceutical Q1 Earnings Call Highlights
Benzinga - 2026-07-30
CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B Est
Yahoo - 2026-07-30
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
SeekingAlpha - 2026-07-30
Takeda Pharmaceutical Company Limited 2027 Q1 - Results - Earnings Call Presentation
Benzinga - 2026-07-29
Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B
Benzinga - 2026-07-29
Takeda Pharmaceutical Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $7.655B Beat $7.060B Estimate
SeekingAlpha - 2026-07-28
Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)
Yahoo - 2026-07-26
How New Phase 3 Psoriasis Data For Zasocitinib At Takeda Pharmaceutical (TSE:4502) Has Changed Its Investment Story
Yahoo - 2026-07-26
Takeda Pharmaceutical (TSE:4502) Reports New Phase 3 Psoriasis Data, Is The 10% Discount Enough?
Yahoo - 2026-07-24
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
Benzinga - 2026-07-17
Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials
Yahoo - 2026-07-16
Change in Siegfried's Management Team
Benzinga - 2026-07-16
World's First End-To-End AI Drug Developer To Power Into Black On Lucrative Partnerships
Yahoo - 2026-07-15
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Yahoo - 2026-07-13
Takeda and Indonesia partner on plasma-derived therapies
Yahoo - 2026-07-13
Moderna, Takeda and Capricor on the verge of notching big drug approvals
SeekingAlpha - 2026-07-08
A New Look At Legend Biotech: Plenty Of Upside For Carvykti
Benzinga - 2026-07-02
Takeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine
SeekingAlpha - 2026-07-02
Ascendis Pharma: Behind The Stock Surge
SeekingAlpha - 2026-06-26
Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Benzinga - 2026-06-24
This $300 Million Biotech May Be Deeply Mispriced: Analyst
SeekingAlpha - 2026-06-24
Takeda Pharmaceutical Company Limited (TAK) Shareholder/Analyst Call - Slideshow
Benzinga - 2026-06-23
Takeda Canada Announces Topline Results For Phase 3, Randomized, Multicenter, Double-Blind Study Comparing Zasocitinib To Deucravacitinib In Adults With Plaque Psoriasis
Benzinga - 2026-06-12
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
SeekingAlpha - 2026-06-11
Takeda Pharmaceutical: The Downside Was Forecastable
Benzinga - 2026-06-11
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med
Benzinga - 2026-06-11
Takeda Says Zasocitinib (TAK-279) Demonstrated Statistical Superiority Over Deucravacitinib In Moderate-To-Severe Plaque Psoriasis Patients
Benzinga - 2026-06-09
FDA Accepts Review Of Takeda's Supplemental Biologics License Application For intravenous ENTYVIO
SeekingAlpha - 2026-05-20
Takeda Pharmaceutical Company Limited (TAK) Q4 FY2025 Earnings Call Transcript
Benzinga - 2026-05-19
Jury Hits Takeda With $885 Million Antitrust Verdict
SeekingAlpha - 2026-05-18
Takeda's Rich Pipeline Optionality Is Worth A 'Buy'
Yahoo - 2026-05-15
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
Yahoo - 2026-05-15
Takeda Pharmaceutical Q4 Earnings Call Highlights
Yahoo - 2026-05-15
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
Yahoo - 2026-05-14
Veeva Commercial Summit to Feature Biopharma's AI Successes and the Path to Agentic Commercial
Yahoo - 2026-05-13
Takeda's Next Wave Of Drugs Has Investors Watching Closely
Yahoo - 2026-05-13
Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo
SeekingAlpha - 2026-05-13
Takeda Pharmaceutical Company Limited (TAK) Q4 2026 Earnings Call Transcript
SeekingAlpha - 2026-05-13
Takeda Pharmaceutical Company Limited 2026 Q4 - Results - Earnings Call Presentation
Benzinga - 2026-05-13
Earnings Scheduled For May 13, 2026
Benzinga - 2026-05-13
Takeda Pharmaceutical Co Sees FY2026 GAAP EPS $0.66.
Benzinga - 2026-05-13
Takeda Pharmaceutical Co Sees FY2026 Adj EPS $3.01; Sees Sales $29.585B
Yahoo - 2026-05-13
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Benzinga - 2026-05-13
Takeda Pharmaceutical Q4 Adj. EPS $0.28 Beats $0.21 Estimate, Sales $6.978B Miss $7.050B Estimate
Yahoo - 2026-05-11
Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Pullback
Yahoo - 2026-05-08
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Yahoo - 2026-05-06
Timothy P. Walbert Joins Patient Square Capital as a Senior Advisor
Yahoo - 2026-05-05
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
Yahoo - 2026-05-05
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?
Yahoo - 2026-05-05
Model N Appoints Thomas Gibbs to Board of Directors
Yahoo - 2026-05-05
Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
Yahoo - 2026-05-05
British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome
Yahoo - 2026-05-04
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Benzinga - 2026-05-04
Takeda Announces That The TAK-881-300 Phase 2/3 Clinical Trial In Patients With Primary Immunodeficiency Disease 1 Met Its Primary Endpoint,
Yahoo - 2026-05-04
Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights
Yahoo - 2026-05-02
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?
Benzinga - 2026-05-01
Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression
Yahoo - 2026-04-30
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Yahoo - 2026-04-30
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
Yahoo - 2026-04-29
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight
Yahoo - 2026-04-28
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference
Yahoo - 2026-04-24
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
Yahoo - 2026-04-23
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
Yahoo - 2026-04-23
Bernstein Upgrades Takeda Pharmaceutical (TAK) to Outperform
Yahoo - 2026-04-22
Will Asceniv Deliver for ADMA in the Upcoming Quarterly Results?
Yahoo - 2026-04-21
Takeda Ends Veritas In Silico Pact As mRNA Focus And Valuation Watched
Yahoo - 2026-04-20
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
Yahoo - 2026-04-20
KROS Rinvatercept: What to Know Before DMD Phase II Starts
Yahoo - 2026-04-17
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
SeekingAlpha - 2026-04-17
Johnson & Johnson: Why I See Downside Ahead
Yahoo - 2026-04-16
Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns?
SeekingAlpha - 2026-04-13
My Top 4 Pharma Picks Under Rising Geopolitical Risk
Benzinga - 2026-04-06
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Benzinga - 2026-04-05
Reported Friday, Denali Therapeutics Regains Full Rights To DNL593 After Takeda Terminates Collaboration, Phase 1/2 FTD-GRN Trial Results Expected By End Of 2026
Benzinga - 2026-04-01
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda
Benzinga - 2026-04-01
Axsome Therapeutics Enters Into An Asset Purchase Agreement To Obtain Exclusive Global Rights To TAK-063 (balipodect) From Takeda, Deal Terms Undisclosed
SeekingAlpha - 2026-03-30
Kamada: From Buy To Hold After 22.4% Surge (Rating Downgrade)
Benzinga - 2026-03-29
Reported Saturday, Takeda's Phase 3 Latitude PsO Data Shows Once-Daily Zasocitinib Achieves 71.4% sPGA 0/1 Response Versus 10.7% For Placebo And 32.1% For Apremilast At Week 16
SeekingAlpha - 2026-03-28
Takeda Pharmaceutical Company Limited (TAK) Discusses Zasocitinib Phase III Psoriasis Data and Commercial Strategy Transcript
SeekingAlpha - 2026-03-28
Takeda Pharmaceutical Company Limited (TAK) Discusses Zasocitinib Phase III Psoriasis Data and Commercial Strategy - Slideshow
SeekingAlpha - 2026-03-25
Takeda: 'Hold' Despite Performance In 2025-2026
Benzinga - 2026-03-23
What's Going On With Eli Lilly On Monday?
Benzinga - 2026-03-23
'Takeda, Lilly Rejected by Supreme Court on Actos Fraud Lawsuit' - Bloomberg
SeekingAlpha - 2026-03-16
Neurocrine Biosciences: The Song Remains The Same
Yahoo - 2026-03-15
Assessing Takeda Pharmaceutical (TSE:4502) Valuation After Strong Multi‑Period Shareholder Returns
Yahoo - 2026-03-13
Rixubis (Takeda Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
SeekingAlpha - 2026-03-12
KalVista Pharmaceuticals: Has Potential But With Caveats
Yahoo - 2026-03-11
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
Yahoo - 2026-03-10
Hemofil M (Takeda Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F
Yahoo - 2026-03-09
Actos Class Action Puts Eli Lilly Legal And Cash Flow Risks In Focus
Yahoo - 2026-03-08
FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment
Yahoo - 2026-03-05
Update: Market Chatter: Takeda Pharmaceutical to Cut 400 US Jobs, Invest in Blood Products
Benzinga - 2026-03-05
Stocks Trading Ex Dividend For Mon., Nov. 19, 2018
Benzinga - 2026-03-05
Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.
SeekingAlpha - 2026-03-04
Takeda Pharmaceutical Company Limited (TAK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Benzinga - 2026-03-04
'Takeda Pharma to cut 400 US jobs in overhaul ahead of CEO switch' - Nikkei Asia
Yahoo - 2026-03-02